Loading stock data…
IONS
$75.28+0.52 (+0.70%)
Market ClosedLast close May 1
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Ionis Pharmaceuticals, Inc. in the Healthcare sector is trading at $75.28. The stock is currently 13% below its 52-week high of $86.74, remaining 8.0% above its 200-day moving average. Technical signals show neutral RSI of 51 and bullish MACD crossover, explaining why IONS maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 51) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$75.28
Potential Upside
5%
Whystock Fair Value$79.04
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus23 analysts
Buy
Mean target$99.65+32.4%
Range$47.00 – $130.00
Fundamentals
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pan...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$12.32B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.40
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-54.84%
Volume
Today's trading volume
1.67M
Recent News
Earnings Beat: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Ionis Pharmaceuticals, Inc. ( NASDAQ:IONS ) just released its first-quarter report and things are looking bullish...
Alnylam Surges After Its Pfizer-Rivaling Blockbuster Jumps Nearly 200%
Alnylam stock popped Thursday on a solid first-quarter beat for its Pfizer-rivaling heart disease drug, Amvuttra.
IONS Q1 Earnings & Sales Beat, Stock Rises on Raised '26 View
Ionis tops Q1 estimates and lifts 2026 outlook, drives shares higher as strong drug sales and milestone revenues fuel growth.
Ionis Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary
Moby summary of Ionis Pharmaceuticals, Inc.'s Q1 2026 earnings call
Ionis Pharmaceuticals Q1 Earnings Call Highlights
Ionis Pharmaceuticals (NASDAQ:IONS) reported sharply higher first-quarter 2026 revenue and raised its full-year outlook, citing accelerating demand for its two commercial products and milestone-driven partner revenue. Management also outlined upcoming regulatory milestones and launch preparations fo